-
Tytuł:
-
Next-Generation Sequencing as an Auxiliary Tool in Pediatric Laryngeal Lymphoma Diagnosis.
-
Autorzy:
-
Munjal T; Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Stanford University, Palo Alto, California.
Vukkadala N; Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Stanford University, Palo Alto, California.
Hazard FK; Division of Hematology, Department of Pathology, Lucile Packard Children's Hospital and Stanford University, Palo Alto, California.
Meister KD; Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Stanford University, Palo Alto, California .
-
Źródło:
-
Pediatrics [Pediatrics] 2021 Nov; Vol. 148 (5). Date of Electronic Publication: 2021 Oct 29.
-
Typ publikacji:
-
Case Reports; Journal Article; Research Support, N.I.H., Extramural
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Elk Grove Village Il : American Academy of Pediatrics
Original Publication: Springfield, Ill., Thomas.
-
MeSH Terms:
-
High-Throughput Nucleotide Sequencing*
Epstein-Barr Virus Infections/*diagnosis
Herpesvirus 4, Human/*genetics
Laryngeal Neoplasms/*diagnosis
Lymphoma, Non-Hodgkin/*diagnosis
Cell-Free Nucleic Acids/blood ; Child ; Cytomegalovirus/genetics ; Herpesvirus 4, Human/isolation & purification ; Humans ; Infratentorial Neoplasms/therapy ; Laryngeal Neoplasms/complications ; Laryngeal Neoplasms/virology ; Laryngitis/diagnosis ; Laryngitis/etiology ; Lymphoma, Non-Hodgkin/complications ; Lymphoma, Non-Hodgkin/virology ; Male ; Medulloblastoma/therapy ; Spinal Neoplasms/therapy ; Tomography, X-Ray Computed ; Tracheitis/diagnosis ; Tracheitis/etiology
-
Grant Information:
-
T32 DC015209 United States DC NIDCD NIH HHS
-
Substance Nomenclature:
-
0 (Cell-Free Nucleic Acids)
-
Entry Date(s):
-
Date Created: 20211030 Date Completed: 20211125 Latest Revision: 20211125
-
Update Code:
-
20240105
-
DOI:
-
10.1542/peds.2020-047662
-
PMID:
-
34716219
-
Lymphomatous involvement of the larynx is a rare entity. We present a case of atypical laryngotracheitis as the initial manifestation of non-Hodgkin's lymphoma in a pediatric patient. The diagnosis was aided through the use of microbial cell-free DNA (mcfDNA) testing, which detected the presence of Epstein-Barr virus in the patient's plasma. This enabled the consideration of an Epstein-Barr virus-related lymphoproliferative process, leading to additional workup and the final diagnosis of lymphoma. To our knowledge, this is the first case of mcfDNA testing leading not simply to an infectious organism, but further to a new oncologic diagnosis. Plasma mcfDNA testing has the potential to inform clinical practice beyond classic infectious disease manifestations. In this article, we review both the possible future applications and the areas of further investigation that remain.
Competing Interests: POTENTIAL CONFLICT OF INTEREST: Dr Munjal serves as consultant for Spiral Therapeutics for work unrelated to this study; Drs Vukkadala, Hazard, and Meister have indicated they have no potential conflicts of interest to disclose.
(Copyright © 2021 by the American Academy of Pediatrics.)
